Cargando…
Direct oral anticoagulant use and risk of severe COVID‐19
BACKGROUND: Hypercoagulability and thromboembolism are prominent features of severe COVID‐19, and ongoing anticoagulant use might be protective. METHODS: We conducted a nationwide register‐based cohort study in Sweden, February through May, 2020, to assess whether ongoing direct oral anticoagulant (...
Autores principales: | Flam, B., Wintzell, V., Ludvigsson, J. F., Mårtensson, J., Pasternak, B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753564/ https://www.ncbi.nlm.nih.gov/pubmed/33258156 http://dx.doi.org/10.1111/joim.13205 |
Ejemplares similares
-
Proton pump inhibitor use and risk of depression and anxiety in children: nationwide cohort study
por: Wang, Yun‐Han, et al.
Publicado: (2022) -
Association between proton pump inhibitor use and risk of pneumonia in children: nationwide self-controlled case series study in Sweden
por: Wang, Yun-Han, et al.
Publicado: (2022) -
Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists
por: Fedorov, Kateryna, et al.
Publicado: (2021) -
Anti–factor Xa activity assays of direct‐acting oral anticoagulants during clinical care: An observational study
por: Sukumar, Smrithi, et al.
Publicado: (2021) -
Impact of oral anticoagulant choice for the secondary prevention of venous thromboembolism on the risk of inpatient bleeding
por: MacLehose, Richard F., et al.
Publicado: (2021)